Brief: Novocure To Present Final Results From Pivotal Phase 3 Metis Trial Of Its Tumor Treating Fields Therapy For Brain Metastases From Non-Small Cell Lung Cancer At 2025 Astro Annual Meeting
29/09/2025 22:02
Sept 29 (Reuters) - Novocure Ltd NVCR.O: NOVOCURE TO PRESENT FINAL RESULTS FROM THE PIVOTAL PHASE 3 METIS TRIAL OF ITS TUMOR TREATING FIELDS (TTFIELDS) THERAPY FOR BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER AT 2025 ASTRO ANNUAL MEETING Source text: ID:nBw2nqrHa Further company coverage: NVCR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovoCure
See all newsOncology firm Novocure says cyberattack exposed US patient records
Novocure Ltd reports results for the quarter ended June 30 - Earnings Summary
Novocure Q2 revenue beats, lifts 2026 outlook
Brief: Novocure Q2 Revenue USD 183.584 Million Vs. IBES Estimate USD 172.4 Million
U.S. STOCKS ON THE MOVE-Kardigan, Energy companies, Take-Two, Accenture